敷尔佳(301371.SZ)：“重组Ⅲ型人源化胶原蛋白冻干纤维”已完成临床试验并取得临床试验总结报告

Core Viewpoint - The company, Fulejia (301371.SZ), has completed clinical trials for its product "Recombinant Type III Humanized Collagen Freeze-Dried Fiber" and has obtained the clinical trial summary report, allowing it to submit registration application materials [1] Group 1 - The product "Recombinant Type III Humanized Collagen Freeze-Dried Fiber" is the company's first shallow injection filler product [1] - Completion of clinical trials and obtaining the summary report signifies the company's readiness to submit registration application materials [1] - This development is significant for the company as it aims to expand into the medical beauty clinic market and enrich its product line [1]